CG Oncology reports 41.8% 24-month CR in Phase 3 BOND-003 for cretostimogene

CG Oncology, Inc.

24-month CR rate of 41.8% (46/110) in BCG-unresponsive HR NMIBC; 12 additional CRs since April 2025 AUA.
90% of 12-month responders remained disease-free at 24 months; 96.6% free from progression to muscle-invasive disease.
No Grade 3+ TRAEs or deaths; median TRAE resolution 1 day; 97.3% completed all treatments.
Company plans BLA submission for cretostimogene in HR NMIBC unresponsive to BCG in Q4 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.